Exclusive: U.S. Chamber Lobbies Against China Drug Registration Revisions That Would Favor Local Generics
This article was originally published in PharmAsia News
Executive Summary
The U.S. Chamber of Commerce is lobbying China FDA over its recent draft drug registration regulations, which would allow approval of generics while an originator’s patent is still valid. Big pharma could face faster and stronger generic competition in China if CFDA finalizes the regulations without revision.